178 related articles for article (PubMed ID: 23841505)
1. Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma.
Xu ZZ; Wang WF; Fu WB; Wang AH; Liu ZY; Chen LY; Guo P; Li JM
Leuk Lymphoma; 2014 May; 55(5):1151-7. PubMed ID: 23841505
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in diffuse large B-cell lymphomas.
Merli M; Ferrario A; Maffioli M; Arcaini L; Passamonti F
Future Oncol; 2015; 11(3):373-83. PubMed ID: 25675120
[TBL] [Abstract][Full Text] [Related]
4. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Jia X; Banwait R; Maiso P; Azab F; Flores L; Manier S; Azab AK; Ghobrial IM
Clin Cancer Res; 2012 Dec; 18(24):6609-22. PubMed ID: 23048077
[TBL] [Abstract][Full Text] [Related]
6. Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Jaeger-Lansky A; Cejka D; Ying L; Preusser M; Hoeflmayer D; Fuereder T; Koehrer S; Wacheck V
Cancer Biol Ther; 2010 Jun; 9(11):919-27. PubMed ID: 20404549
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.
Zhu Y; Zhang X; Liu Y; Zhang S; Liu J; Ma Y; Zhang J
Tumour Biol; 2012 Oct; 33(5):1349-62. PubMed ID: 22492237
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
10. The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo.
Xu CX; Li Y; Yue P; Owonikoko TK; Ramalingam SS; Khuri FR; Sun SY
PLoS One; 2011; 6(6):e20899. PubMed ID: 21695126
[TBL] [Abstract][Full Text] [Related]
11. Combined targeting of mTOR and c-MET signaling pathways for effective management of epithelioid sarcoma.
Imura Y; Yasui H; Outani H; Wakamatsu T; Hamada K; Nakai T; Yamada S; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
Mol Cancer; 2014 Aug; 13():185. PubMed ID: 25098767
[TBL] [Abstract][Full Text] [Related]
12. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
13. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
Márk Á
Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
[TBL] [Abstract][Full Text] [Related]
14. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
15. Schedule-dependent inhibition of T-cell lymphoma cells by cotreatment with the mTOR inhibitor everolimus and anticancer drugs.
Huang JJ; Li ZM; Huang Y; Huang Y; Tian Y; He XX; Xiao J; Lin TY
Invest New Drugs; 2012 Feb; 30(1):223-35. PubMed ID: 20960030
[TBL] [Abstract][Full Text] [Related]
16. Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway.
Li X; Wang X; Zhang M; Li A; Sun Z; Yu Q
Cell Biochem Biophys; 2014 Nov; 70(2):1357-62. PubMed ID: 24902540
[TBL] [Abstract][Full Text] [Related]
17. In vivo and in vitro effects of RAD001 on bladder cancer.
Vasconcelos-Nóbrega C; Pinto-Leite R; Arantes-Rodrigues R; Ferreira R; Brochado P; Cardoso ML; Palmeira C; Salvador A; Guedes-Teixeira CI; Colaço A; Palomino LF; Lopes C; Santos L; Oliveira PA
Urol Oncol; 2013 Oct; 31(7):1212-21. PubMed ID: 22169072
[TBL] [Abstract][Full Text] [Related]
18. Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Gaudio E; Tarantelli C; Ponzoni M; Odore E; Rezai K; Bernasconi E; Cascione L; Rinaldi A; Stathis A; Riveiro E; Cvitkovic E; Zucca E; Bertoni F
Oncotarget; 2016 Sep; 7(36):58142-58147. PubMed ID: 27494885
[TBL] [Abstract][Full Text] [Related]
19. Aberrant activation of the mTOR pathway and anti-tumour effect of everolimus on oesophageal squamous cell carcinoma.
Hirashima K; Baba Y; Watanabe M; Karashima RI; Sato N; Imamura Y; Nagai Y; Hayashi N; Iyama KI; Baba H
Br J Cancer; 2012 Feb; 106(5):876-82. PubMed ID: 22333597
[TBL] [Abstract][Full Text] [Related]
20. Low dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.
Jin Z; Qing K; Ouyang Y; Liu Z; Wang W; Li X; Xu Z; Li J
J Exp Clin Cancer Res; 2016 Mar; 35():52. PubMed ID: 27009084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]